Zobrazeno 1 - 10
of 1 640
pro vyhledávání: '"Escudié, F."'
Publikováno v:
In Microelectronics Reliability November 2022 138
Publikováno v:
In Microelectronics Reliability September 2017 76-77:685-691
Autor:
Hendrickx S; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Feijens PB; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Escudié F; Drugs for Neglected Diseases initiative, 1202 Geneva, Switzerland., Chatelain E; Drugs for Neglected Diseases initiative, 1202 Geneva, Switzerland., Maes L; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium., Caljon G; Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, 2610 Antwerp, Belgium.
Publikováno v:
ACS infectious diseases [ACS Infect Dis] 2024 Jun 14; Vol. 10 (6), pp. 2101-2107. Date of Electronic Publication: 2024 May 11.
Autor:
Petit PR; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Touret F; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Driouich JS; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Cochin M; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Luciani L; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Bernadin O; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Laprie C; Laboratoire Vet-Histo, Marseille, France., Piorkowski G; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Fraisse L; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Sjö P; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Mowbray CE; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Escudié F; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Scandale I; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Chatelain E; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., de Lamballerie X; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France., Solas C; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France.; Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, APHM, Marseille, France., Nougairède A; Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France.
Publikováno v:
Heliyon [Heliyon] 2024 May 08; Vol. 10 (10), pp. e30862. Date of Electronic Publication: 2024 May 08 (Print Publication: 2024).
Publikováno v:
In Microelectronics Reliability September 2016 64:88-92
Autor:
Bouzidi HS; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Driouich JS; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Klitting R; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Bernadin O; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Piorkowski G; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Amaral R; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Fraisse L; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Mowbray CE; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Scandale I; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Escudié F; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Chatelain E; Drugs for Neglected Diseases Initiative, Geneva, Switzerland., de Lamballerie X; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Nougairède A; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France., Touret F; Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France. Electronic address: franck.touret@univ-amu.fr.
Publikováno v:
Antiviral research [Antiviral Res] 2024 Feb; Vol. 222, pp. 105814. Date of Electronic Publication: 2024 Jan 24.
Autor:
Box HJ; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Sharp J; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Pennington SH; Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Kijak E; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Tatham L; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Caygill CH; Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Lopeman RC; Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Jeffreys LN; Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Herriott J; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Neary M; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Valentijn A; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Pertinez H; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Curley P; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Arshad U; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Rajoli RKR; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK., Jochmans D; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, 3000, Leuven, Belgium and the Global Virus Network (GVN), Baltimore, MD, USA., Vangeel L; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, 3000, Leuven, Belgium and the Global Virus Network (GVN), Baltimore, MD, USA., Neyts J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, 3000, Leuven, Belgium and the Global Virus Network (GVN), Baltimore, MD, USA., Chatelain E; Drugs for Neglected Diseases initiative (DNDi), Research and Development, 1202, Geneva, Switzerland., Escudié F; Drugs for Neglected Diseases initiative (DNDi), Research and Development, 1202, Geneva, Switzerland., Scandale I; Drugs for Neglected Diseases initiative (DNDi), Research and Development, 1202, Geneva, Switzerland., Rannard S; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK.; Department of Chemistry, University of Liverpool,Liverpool L7 3NY, UK., Stewart JP; Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Biagini GA; Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK., Owen A; Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L7 3NY, UK.; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool L7 3NY, UK.
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Jan 03; Vol. 79 (1), pp. 172-178.
Autor:
Abdelnabi, R, Foo, CS, Jochmans, D, Vangeel, L, De Jonghe, S, Augustijns, P, Mols, R, Weynand, B, Wattanakul, T, Hoglund, RM, Tarning, J, Mowbray, CE, Sjö, P, Escudié, F, Scandale, I, Chatelain, E, Neyts, J
Publikováno v:
Nature communications. 13(1)
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df02a56b06fd0f38fc6337ca6b38f57c
https://pubmed.ncbi.nlm.nih.gov/35169114
https://pubmed.ncbi.nlm.nih.gov/35169114
Autor:
Chesneau B; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Ivashchenko V; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Habib C; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Gaston V; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Escudié F; Département d'anatomopathologie, IUCT Oncopole, Toulouse, France., Morel G; Service de Génétique Médicale, CHU de Rennes, Rennes, France., Capri Y; Service de Génétique Médicale, Hôpital Robert Debré, APHP, Paris, France., Vincent-Delorme C; Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France., Calvas P; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Chassaing N; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Plaisancié J; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France. plaisancie.j@chu-toulouse.fr.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France. plaisancie.j@chu-toulouse.fr.; INSERM U1214, ToNIC, Université Toulouse III, Toulouse, France. plaisancie.j@chu-toulouse.fr.
Publikováno v:
European journal of human genetics : EJHG [Eur J Hum Genet] 2023 May; Vol. 31 (5), pp. 607.
Autor:
Chesneau B; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Ivashchenko V; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Habib C; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Gaston V; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France., Escudié F; Département d'anatomopathologie, IUCT Oncopole, Toulouse, France., Morel G; Service de Génétique Médicale, CHU de Rennes, Rennes, France., Capri Y; Service de Génétique Médicale, Hôpital Robert Debré, APHP, Paris, France., Vincent-Delorme C; Service de Génétique Clinique, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France., Calvas P; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Chassaing N; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France., Plaisancié J; Service de Génétique Médicale, Hôpital Purpan, CHU de Toulouse, Toulouse, France. plaisancie.j@chu-toulouse.fr.; Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), CHU de Toulouse, Toulouse, France. plaisancie.j@chu-toulouse.fr.; INSERM U1214, ToNIC, Université Toulouse III, Toulouse, France. plaisancie.j@chu-toulouse.fr.
Publikováno v:
European journal of human genetics : EJHG [Eur J Hum Genet] 2023 May; Vol. 31 (5), pp. 526-530. Date of Electronic Publication: 2022 Nov 21.